Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAST-A cardiac arrest trial
2025-521283-35-00Phase 3Authorised
- Sponsor
- TioHundra
- Start
- Apr 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of vasopressin, hydrocortisone, methylprednisolone and epinephrine in cardiac arrest (SCA) (2 arms), sponsored by TioHundra. Primary endpoint: Survival at 30 days. Planned start Apr 2025; status: authorised.
02
Drugs
vasopressinhydrocortisonemethylprednisoloneepinephrine
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2025-521283-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521283-35-00.